arrow
Y

Yanwen Jiang

university college london
H指数:43
被引数:7,221

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

CRISTALLO:一项关于Venetoclax-Obinutuzumab与Fludarabine、Cyclophosphamide和Rituximab或Bendamustine-Rituximab治疗无Del(17p)或TP53突变初治慢性淋巴细胞白血病患者Ⅲ期试验的结果

BLOOD
IF23.1
2024-11-050
PRE
Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

慢性淋巴细胞白血病患者中接受固定疗程Venetoclax-Obinutuzumab或Chlorambucil-Obinutuzumab治疗时的克隆性造血:来自随机CLL14试验的见解

BLOOD
IF23.1
2024-11-050
PRE
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia (vol 14, 2147, 2023)
2023-10-232
OAAI
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
2023-04-1845
OAAI
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
2023-01-1715
OAAI
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
2021-01-1978
OAAI
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL
2019-04-2365
OAAI